Alvotech’s Simponi Rival Begins Pharmacokinetic Study
The Icelandic Firm Is Also Expanding Its Marketing Partnership With Fuji Pharma
Alvotech’s Simponi rival enters Phase I trials after a dynamic year for the company’s development and commercialization program. Meanwhile, the biosimilars developer has also expanded its Japanese collaboration with Fuji Pharma.
You may also be interested in...
Teva Will Stick To Hybrid Biosimilar Model, With Cash In Its Thinking
Teva’s senior management spoke at length about the company’s ambitions in the biosimilar space, ahead of the planned US launch of partner Alvotech’s AVT02 proposed interchangeable high-concentration (Humira) adalimumab biosimilar on 1 July.
FDA Promises Interchangeability For Alvotech’s 100mg/ml Humira Rival – If It Passes Inspection
Alvotech has been bolstered by a US FDA confirmation that its AVT02 adalimumab candidate can be approved as an interchangeable biosimilar based on the data provided in its filing – but first, the Icelandic firm must pass an upcoming facility inspection.
Alvotech Targets MENA In Multi-Biosimilar Commercialization Deal
Three firms across Europe and North Africa sign to sell Alvotech biosimilar candidates in 19 MENA countries as the Icelandic developer shifts focus from R&D to global commercialization.